BlockBeats News, May 6th, Anti-aging company NewLimit, founded by Coinbase CEO Brian Armstrong, announced the completion of a $130 million Series B funding round. This round of funding was led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, and Khosla Ventures, among others.
NewLimit aims to extend people's healthy lifespan through genetic programming of cells. Founded four years ago by Brian Armstrong, former GV partner Blake Bryers, and stem cell professor Jacob Kimmel, the company claims to have made significant progress in developing a therapeutic approach to rejuvenate aging cells.
The company has identified three prototype drugs that can reprogram liver cells. Bryers stated that laboratory experiments at NewLimit have shown that this regeneration therapy can restore the cells' ability to process fat and alcohol. The company measures its progress by comparing how cells from young and old individuals respond to these substances. Liver cells processed through NewLeaf epigenetic reprogramming behave more like young cells.
Despite promising early results, NewLimit is still several years away from starting human trials.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。